The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.
Kim N. Chi
Consultant or Advisory Role - Janssen
Honoraria - Janssen
Research Funding - Janssen
Thian San Kheoh
Employment or Leadership Position - Janssen
Stock Ownership - Johnson & Johnson
Charles J. Ryan
Honoraria - Janssen
Arturo Molina
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Joaquim Bellmunt
Consultant or Advisory Role - Cougar Biotechnology
Nicholas J. Vogelzang
Consultant or Advisory Role - Amgen; Bayer; Celgene; Cougar Biotechnology; Dendreon; GlaxoSmithKline; Johnson & Johnson; Novartis; Pfizer; Takeda; Veridex
Honoraria - Amgen; Astellas Pharma; Bayer; Cougar Biotechnology; Dendreon; GlaxoSmithKline; Janssen; Johnson & Johnson; Novartis; Pfizer; Sanofi ; Veridex
Research Funding - Algeta; Amgen; Cougar Biotechnology; Johnson & Johnson; Takeda; Veridex
Dana E. Rathkopf
Research Funding - Johnson & Johnson
Karim Fizazi
Consultant or Advisory Role - Janssen
Honoraria - Janssen
Philip W. Kantoff
Consultant or Advisory Role - Janssen
Research Funding - Janssen
Jinhui Li
Employment or Leadership Position - Janssen Research & Development
Johann Sebastian De Bono
Employment or Leadership Position - The Institute of Cancer Research
Consultant or Advisory Role - Astellas Pharma; Johnson & Johnson; Medivation
Honoraria - Astellas Pharma; Johnson & Johnson; Medivation
Howard I. Scher
Consultant or Advisory Role - Aragon Pharmaceuticals (U); Bristol-Myers Squibb; Celgene (U); Dendreon; Endo/Orion Pharmaceuticals; Exelixis (U); Foundation Medicine (U); Genentech; Janssen (U); Johnson & Johnson (U); Medivation (U); Millennium (U); Novartis; Ortho Biotech; Sanofi ; Senior Scientific; Takeda (U)
Research Funding - Aragon Pharmaceuticals; Bristol-Myers Squibb; Exelixis; Janssen; Janssen Research & Development; Medivation